2. Academic Validation
  3. vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis

vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis

  • Int J Biol Macromol. 2025 Sep 7;328(Pt 1):147514. doi: 10.1016/j.ijbiomac.2025.147514.
Yafei Wu 1,  Wenjing Diao 1,  Xue Zhang 2,  Dahong Chen 1,  Huihua Yang 1,  Lin Zhong 3,  Chuanxing Wu 4,  Qin Li 5
Affiliations

Affiliations

  • 1 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China.
  • 2 Shanghai Eye Diseases Prevention &Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, PR China.
  • 3 Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China.
  • 4 Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China. Electronic address: doc_zf@163.com.
  • 5 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China; Shanghai Eye Diseases Prevention &Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, PR China. Electronic address: liqin0626@hotmail.com.
PMID: 40925433 DOI: 10.1016/j.ijbiomac.2025.147514
Abstract

While vault RNA1-1 (vtRNA1-1) has been implicated in tumor biology, its specific role in Cancer stemness and regorafenib resistance remains unexplored. In this study, we identify vtRNA1-1 as a critical regulator of Cancer stemness and chemoresistance in Hepatocellular carcinoma (HCC). vtRNA1-1 enhances stemness properties by modulating the nuclear accumulation of Nanog, a core transcription factor. This pro-stemness effect could be counteracted through Autophagy activation using rapamycin or nutrient starvation. Importantly, we demonstrate that regorafenib treatment induces vtRNA1-1 upregulation, and that acquired resistance correlates with impaired vtRNA1-1 processing, leading to vtRNA1-1 accumulation and reduced generation of small vault RNAs (svRNAs). Genetic silencing of vtRNA1-1 effectively restored regorafenib sensitivity in resistant cells by promoting Apoptosis and suppressing stemness markers. Our findings establish vtRNA1-1 as a novel oncogenic driver and reveal its potential as both a predictive biomarker for regorafenib response and a therapeutic target for overcoming drug resistance.

Keywords

Regorafenib resistance; Stemness; Vault RNA1-1.

Figures
Products
Inhibitors & Agonists
Other Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z